Headache News and Research

Latest Headache News and Research

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.

14 Dec 2012

FDA approves Novartis Signifor injection for treatment of Cushing's disease

Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.

14 Dec 2012

Smoking ‘worsens hangovers’

People who smoke more than usual on the same day as drinking heavily are at increased risk for a hangover the following morning, with heavier smoking leading to a worse hangover, researchers say.

14 Dec 2012

Top-line results from Durata Therapeutics’ dalbavancin Phase 3 study on ABSSSI

Durata Therapeutics, Inc. today announced preliminary, top-line results for its DISCOVER 1 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response") Phase 3 study of dalbavancin, which is under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including MRSA (methicillin resistant Staphylococcus aureus).

11 Dec 2012

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults.

11 Dec 2012

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.

11 Dec 2012

Almirall, Forest Laboratories' Tudorza Pressair now available in the U.S. pharmacies

Forest Laboratories, Inc. and Almirall, S.A. announced today that Tudorza Pressair (aclidinium bromide inhalation powder) 400mcg is now available in pharmacies throughout the United States.

11 Dec 2012

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene International Sàrl today announced that results from a study evaluating the combination of REVLIMID (lenalidomide) plus VIDAZA (azacitidine) in patients 60 years or older with untreated acute myeloid leukemia (AML) were presented at the American Society of Hematology annual meeting in Atlanta, GA.

11 Dec 2012

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo.

10 Dec 2012

Sanofi Pasteur’s IMOJEV vaccine against Japanese encephalitis is now available in Australia

Sanofi Pasteur, the vaccines division of Sanofi, announced today that IMOJEV vaccine against Japanese encephalitis (JE) is now available in Australia.

10 Dec 2012

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca today announced the presentation of important new data from studies of FASLODEX (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

5 Dec 2012

Smokers more likely to report hangover symptoms after heavy drinking

People who like to smoke when they drink may be at greater risk of suffering a hangover the next morning, according to a study in the January 2013 issue of the Journal of Studies on Alcohol and Drugs.

5 Dec 2012

Guineafowl may spread Crimean-Congo hemorrhagic fever virus

Turkey raises and releases thousands of non-native guineafowl to eat ticks that carry the deadly Crimean-Congo hemorrhagic fever virus. Yet research suggests guineafowl eat few ticks, but carry the parasites on their feathers, possibly spreading the disease they were meant to stop, says a Turkish biologist working at the University of Utah.

30 Nov 2012

Eisai announces FDA acceptance of AcipHex NDA for priority review

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA) for AcipHex Delayed-Release Sprinkle Capsules 5mg and 10mg for the proposed indication of healing of Gastroesophageal Reflux Disease (GERD), maintenance of healing of GERD and improvement of symptoms of GERD in children 1 to 11 years of age.

30 Nov 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

CSL, PharmaJet partner for needle-free delivery of Afluria influenza vaccine

PharmaJet Inc. has entered into a collaboration with CSL Limited to enable Afluria influenza vaccine to be delivered with the PharmaJet Stratis needle-free jet injector, as soon as the 2013-2014 flu season.

30 Nov 2012

Tips to prevent holiday headaches

Holidays are a time for family, friends, and happy memories. But those joyful moments can be associated with stress – from marathon shopping, preparing for celebrations, and traveling. Stress and other stimuli may trigger or increase your headaches.

30 Nov 2012

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring key sets of VIMPAT® (lacosamide) C-V data at the 66th Annual Meeting of the American Epilepsy Society (AES) in San Diego, Calif., November 30 - December 4.

29 Nov 2012

Brain microhemorrhages more common among high altitude cerebral edema survivors

New magnetic resonance imaging (MRI) research shows that mountain climbers who experience a certain type of high altitude sickness have traces of bleeding in the brain years after the initial incident, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

28 Nov 2012

$Study identifies fractional anisotropy as predictor of brain damage after TBI$

Study identifies fractional anisotropy as predictor of brain damage after TBI

Using a special magnetic resonance imaging (MRI) technique to image patients with mild traumatic brain injury (MTBI), researchers have identified a biomarker that may predict which patients will do well over the long term, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

26 Nov 2012

Headache News and Research

Latest Headache News and Research

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

FDA approves Novartis Signifor injection for treatment of Cushing's disease

Smoking ‘worsens hangovers’

Top-line results from Durata Therapeutics’ dalbavancin Phase 3 study on ABSSSI

Janssen announces U.S. prescribing information update for EDURANT tablets

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

Almirall, Forest Laboratories' Tudorza Pressair now available in the U.S. pharmacies

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Sanofi Pasteur’s IMOJEV vaccine against Japanese encephalitis is now available in Australia

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

Smokers more likely to report hangover symptoms after heavy drinking

Guineafowl may spread Crimean-Congo hemorrhagic fever virus

Eisai announces FDA acceptance of AcipHex NDA for priority review

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

CSL, PharmaJet partner for needle-free delivery of Afluria influenza vaccine

Tips to prevent holiday headaches

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

Brain microhemorrhages more common among high altitude cerebral edema survivors

Study identifies fractional anisotropy as predictor of brain damage after TBI

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in